Skip to main content
Top
Published in: Diabetes Therapy 2/2016

Open Access 01-06-2016 | Original Research

Frequency of Lipohypertrophy and Associated Risk Factors in Young Patients with Type 1 Diabetes: A Cross-Sectional Study

Authors: Ayman A. Al Hayek, Asirvatham A. Robert, Rim B. Braham, Mohamed A. Al Dawish

Published in: Diabetes Therapy | Issue 2/2016

Login to get access

Abstract

Introduction

The objective of this study was to investigate the frequency of lipohypertrophy (LH) and the associated risk factors in young patients with type 1 diabetes mellitus (T1DM).

Methods

This cross-sectional study was conducted on a sample of 174 patients with T1DM (aged 13–18 years) treated with multiple daily insulin injections for a minimum duration of 1 year. The study was performed at the Diabetes Treatment Center, Prince Sultan Military Medical City (Riyadh, Saudi Arabia), between July 2015 and September 2015. Information regarding patients’ age, weight, height, adjusted body mass index (BMI), period of the diabetic condition, length of needle used, number of injections per day, injection locations, insulin regimen, and glycosylated hemoglobin (HbA1c) were recorded. LH was assessed using the palpation technique.

Results

Nearly 46% of patients were found to reuse needles, while 42.5% failed to alternate the injection site and 23% revealed unexplained hypoglycemic events. A substantial percentage of patients (approximately 47%) showed grade 1 LH, followed by 33.7% with grade 2 and 19.3% with grade 3 LH. A higher frequency of LH was observed in the thigh region (n = 28, 33.7%) than in the arm, which was second highest (n = 23, 27.7%). Patients aged ≥16 years showed a higher frequency of LH than those aged <16 years. Patients with uncontrolled diabetes mellitus had a greater likelihood of having LH (59.5%) than those with controlled diabetes (20.8%). Significant differences in LH were observed based on needle length, needle reuse, and rotation of the injection sites. On performing regression analysis, the independent risk factors for LH were found to be as follows: higher BMI, higher HbA1c, a higher number of injection sites, a higher rate of needle reuse and failed to alternate the injection site.

Conclusion

As the frequency of LH was found to be high in Saudi patients with T1DM, it is essential to educate patients on the risk factors for LH and on diabetic control.
Literature
2.
go back to reference Al-Hayek AA, Robert AA, Braham RB, et al. Frequency and associated risk factors of recurrent diabetic ketoacidosis among Saudi adolescents with type 1 diabetes mellitus. Saudi Med J. 2015;36:216–20.CrossRefPubMedPubMedCentral Al-Hayek AA, Robert AA, Braham RB, et al. Frequency and associated risk factors of recurrent diabetic ketoacidosis among Saudi adolescents with type 1 diabetes mellitus. Saudi Med J. 2015;36:216–20.CrossRefPubMedPubMedCentral
3.
go back to reference Oikawa Y. Shimada A [Type 1 diabetes]. Nihon Rinsho. 2015;73:1997–2002.PubMed Oikawa Y. Shimada A [Type 1 diabetes]. Nihon Rinsho. 2015;73:1997–2002.PubMed
4.
5.
go back to reference Thabit H, Hovorka R. Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opin Drug Deliv. 2015;30:1–12. Thabit H, Hovorka R. Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opin Drug Deliv. 2015;30:1–12.
6.
go back to reference Davey B, Segal DG. Self-monitoring of blood glucose measurements and glycaemic control in a managed care paediatric type 1 diabetes practice. S Afr Med J. 2015;105:405–7.CrossRefPubMed Davey B, Segal DG. Self-monitoring of blood glucose measurements and glycaemic control in a managed care paediatric type 1 diabetes practice. S Afr Med J. 2015;105:405–7.CrossRefPubMed
7.
go back to reference De Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2:168–79.CrossRefPubMed De Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2:168–79.CrossRefPubMed
8.
go back to reference Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39:445–53.CrossRefPubMed Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39:445–53.CrossRefPubMed
9.
go back to reference Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36(Suppl 2):S3–18.CrossRefPubMed Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36(Suppl 2):S3–18.CrossRefPubMed
10.
go back to reference Ji J, Lou Q. Insulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010. Curr Med Res Opin. 2014;30:1087–93.CrossRefPubMed Ji J, Lou Q. Insulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010. Curr Med Res Opin. 2014;30:1087–93.CrossRefPubMed
11.
go back to reference Berard L, Cameron B. Injection technique practices in a population of Canadians with diabetes: results from a recent patient/diabetes educator survey. Can J Diabetes. 2015;39:146–51.CrossRefPubMed Berard L, Cameron B. Injection technique practices in a population of Canadians with diabetes: results from a recent patient/diabetes educator survey. Can J Diabetes. 2015;39:146–51.CrossRefPubMed
12.
go back to reference Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog). Diabet Med. 1998;15:1063–4.CrossRefPubMed Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog). Diabet Med. 1998;15:1063–4.CrossRefPubMed
13.
go back to reference Hajheydari Z, Kashi Z, Akha O, Akbarzadeh S. Frequency of lipodystrophy induced by recombinant human insulin. Eur Rev Med Pharmacol Sci. 2011;15:1196–201.PubMed Hajheydari Z, Kashi Z, Akha O, Akbarzadeh S. Frequency of lipodystrophy induced by recombinant human insulin. Eur Rev Med Pharmacol Sci. 2011;15:1196–201.PubMed
14.
go back to reference Omar MA, El-Kafoury AA, El-Araby RI. Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors. BMC Res Notes. 2011;4:290.CrossRefPubMedPubMedCentral Omar MA, El-Kafoury AA, El-Araby RI. Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors. BMC Res Notes. 2011;4:290.CrossRefPubMedPubMedCentral
15.
go back to reference Al-Hayek AA, Robert AA, Abbas HM, et al. Assessment of health-related quality of life among adolescents with type 1 diabetes mellitus in Saudi Arabia. Saudi Med J. 2014;35(7):712–7. Al-Hayek AA, Robert AA, Abbas HM, et al. Assessment of health-related quality of life among adolescents with type 1 diabetes mellitus in Saudi Arabia. Saudi Med J. 2014;35(7):712–7.
16.
go back to reference Lukacs A, Varga B, Kiss-Toth E, Soos A, Barkai L. Factors influencing the diabetes-specific health-related quality of life in children and adolescents with type 1 diabetes mellitus. J Child Health Care. 2014;18:253–60. Lukacs A, Varga B, Kiss-Toth E, Soos A, Barkai L. Factors influencing the diabetes-specific health-related quality of life in children and adolescents with type 1 diabetes mellitus. J Child Health Care. 2014;18:253–60.
17.
go back to reference Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care. 2002;25:634.CrossRefPubMed Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care. 2002;25:634.CrossRefPubMed
18.
go back to reference Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104:106–10.CrossRefPubMed Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104:106–10.CrossRefPubMed
19.
go back to reference Johansson UB, Amsberg S, Hannerz L, et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care. 2005;28:2025–7.CrossRefPubMed Johansson UB, Amsberg S, Hannerz L, et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care. 2005;28:2025–7.CrossRefPubMed
20.
21.
go back to reference Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4:661–7.CrossRefPubMed Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4:661–7.CrossRefPubMed
22.
go back to reference de Villiers FP. Lipohypertrophy-a complication of insulin injections. S Afr Med J. 2005;95:858–9.PubMed de Villiers FP. Lipohypertrophy-a complication of insulin injections. S Afr Med J. 2005;95:858–9.PubMed
23.
go back to reference Nagesh VS, Kalra S. Type 1 diabetes: syndromes in resource-challenged settings. J Pak Med Assoc. 2015;65:681–5.PubMed Nagesh VS, Kalra S. Type 1 diabetes: syndromes in resource-challenged settings. J Pak Med Assoc. 2015;65:681–5.PubMed
24.
go back to reference Al Ajlouni M, Abujbara M, Batieha A, Ajlouni K. Prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus. Int J Endocrinol Metab. 2015;13:e20776. Al Ajlouni M, Abujbara M, Batieha A, Ajlouni K. Prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus. Int J Endocrinol Metab. 2015;13:e20776.
Metadata
Title
Frequency of Lipohypertrophy and Associated Risk Factors in Young Patients with Type 1 Diabetes: A Cross-Sectional Study
Authors
Ayman A. Al Hayek
Asirvatham A. Robert
Rim B. Braham
Mohamed A. Al Dawish
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 2/2016
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-016-0161-3

Other articles of this Issue 2/2016

Diabetes Therapy 2/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.